Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.
Biomaterials
; 272: 120791, 2021 05.
Article
in En
| MEDLINE
| ID: mdl-33831739
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prodrugs
/
Nanoparticles
/
Neoplasms
Limits:
Animals
Language:
En
Journal:
Biomaterials
Year:
2021
Document type:
Article
Country of publication: